Call for proposals for the Innovative Medicines Initiative's 6th Call for Proposals
The European Commission has published the Innovative Medicines Initiative's 6th Call for Proposals. The call consists of two topics: - 'Innovative trial design and clinical drug development'; - 'Learning from success and failure and getting drugs into bad bugs'. The first topic seeks to fulfil three objectives: - increase the efficiency of antibiotic research and development through analysing pre-clinical and clinical data sets shared and making recommendations for the development of novel antibiotic agents; - establish investigator networks and surveillance programmes to support antibacterial clinical development; - conduct prospective clinical trials with novel trial designs to deliver safety, pharmacology, and proof of efficacy data for novel agents directed towards treatment, prevention or sequelae of infections due to priority pathogens and if possible to validate novel bacterial identification diagnostics or clinical endpoints with the aim of reducing the size and cost of clinical trials. The second topic has two objectives: - improve permeability of drugs into Gram-negative bacteria; - gain an increased level of overall understanding of penetration into and efflux out of Gram-negative bacterial cells, and knowledge to improve template selection for novel drug discovery efforts. The Innovative Medicines Initiative Joint Undertaking is a public-private partnership aiming to foster collaboration between all relevant stakeholders including large and small biopharmaceutical and healthcare companies, regulators, academia and patients.To see the official call announcement, please consult: here To see partnership requests for this call, please see the following: http://cordis.europa.eu/partners/web/guest/calls